MacroGenics Inc. (NASDAQ:MGNX) shares fell 1.9% during trading on Friday . The stock traded as low as $31.11 and last traded at $31.75, with a volume of 109,807 shares traded. The stock had previously closed at $32.35.

Several brokerages have recently commented on MGNX. BTIG Research began coverage on MacroGenics in a report on Thursday, April 7th. They set a “buy” rating and a $35.00 price objective for the company. Morgan Stanley reaffirmed a “hold” rating on shares of MacroGenics in a research note on Thursday, June 30th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of MacroGenics in a research note on Tuesday, June 14th. Leerink Swann reaffirmed an “outperform” rating and issued a $47.00 target price on shares of MacroGenics in a research note on Thursday, May 19th. Finally, Zacks Investment Research lowered MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $40.88.

The firm’s 50 day moving average is $27.57 and its 200 day moving average is $21.90. The company’s market capitalization is $1.09 billion.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 EPS for the quarter, topping the consensus estimate of ($0.02) by $1.14. During the same period last year, the business earned ($0.71) EPS. The company earned $80.67 million during the quarter, compared to the consensus estimate of $27.22 million. The firm’s quarterly revenue was up 1100.4% compared to the same quarter last year. Analysts forecast that MacroGenics Inc. will post ($2.08) EPS for the current fiscal year.

In related news, SVP Jon Marc Wigginton sold 20,000 shares of MacroGenics stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $30.78, for a total transaction of $615,600.00. Following the sale, the senior vice president now owns 20,000 shares of the company’s stock, valued at approximately $615,600. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Lynn Cilinski sold 5,000 shares of MacroGenics stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the sale, the vice president now directly owns 6,923 shares in the company, valued at approximately $173,075. The disclosure for this sale can be found here.

A number of hedge funds have modified their holdings of MGNX. Jennison Associates LLC increased its stake in shares of MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock valued at $8,282,000 after buying an additional 909 shares during the period. California State Teachers Retirement System increased its stake in shares of MacroGenics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 58,401 shares of the biopharmaceutical company’s stock valued at $1,809,000 after buying an additional 1,038 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in shares of MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock valued at $1,386,000 after buying an additional 20,929 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock valued at $2,902,000 after buying an additional 45,422 shares during the period.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.